Latest News
WuXi Biologics (Cayman) Inc.
- What WuXi Biologics Buyers Were Betting On
- Wuxi Biologics (Cayman) Inc. Estimates – DUS:1FW2
- WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity into Commercial Certainty
- What WuXi Biologics Buyers Were Betting On
- HKD 59.51 consensus target leaves WuXi Biologics stock 22.35 percent below target
- WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence
- Everbright maintains Buy for WuXi Biologics stock, citing RMB 11.79 billion revenue
- How FDA Inspection Success At WuXi Biologics Stock Has Changed Its Investment Story
Headlines from the last 30 days, linking to the original publishers. See all market news →